18:00:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning DEAR 0.00 SEK
2024-05-08 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2024-01-31 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning DEAR 0.00 SEK
2023-04-12 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning DEAR 0.00 SEK
2022-04-07 Årsstämma 2022

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Duearity är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling och produktion av tekniska lösningar för behandling och lindring av tinnitus. Produktportföljen inkluderar exempelvis bolagets egenutvecklade produkter Tinearity och Duearity. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs inom Sverige.
2023-06-05 08:00:00

Duearity has conducted a user study to measure the immediate effect of using Tinearity G1 for tinnitus relief. 22 people who are bothered by tinnitus participated in the study, of which one person was excluded. All 22 people experienced a relief of symptoms.

Duearity conducted a user study at the end of April this year in which 22 people with tinnitus participated, of which 21 were included in the study results. Firstly, the purpose of the study was to measure the immediate relief of the tinnitus symptoms. Secondly, the aim was to measure side effects, for example skin irritation and dizziness or nausea caused by mechanical vibration from Tinearity G1. The study will be reviewed by the FDA in the US as well as Duearity's European certification body Intertek.
 
In the user study, people over 18 years of age with normal hearing in at least one ear and with tonal tinnitus (monotonic tinnitus) were included. The participants' hearing and tinnitus sounds (frequency and amplitude) were measured. One person was excluded from the statistical data because the subject had a mild hearing loss in both ears. Despite the hearing loss, the subject experienced relief from the tinnitus symptoms.
 
Participants indicated on a five-point scale whether they experienced relief, where 3-5 corresponded to clearly noticeable (3), partially masked (4) and total masking (5). 1-2 on the scale corresponded to no masking (1) and noticeable masking (2). 21 included people indicated 3 to 5 on the scale, which means that all experienced a relief of their tinnitus. One person experienced a side effect of dizziness and rated this as a 3 on a scale of 1-5. 1 corresponded to no discomfort and 5 corresponded to severe discomfort.
 
A very interesting observation in the user study is that subjects with a tinnitus frequency that exceeds the white noise frequency experienced relief of tinnitus symptoms. This phenomenon is so interesting that Duearity intends to investigate more how the Tinearity G1 masks tinnitus frequencies that exceed the Tinearity G1's maximum frequency height.

Tinearity G1 is a CE-marked medical technology device that is intended to be used to relieve tinnitus, or to be used as a sound source in sound therapy when treated with Tinnitus Retraining Therapy, TRT. Tinearity G1 is intended for being used by people with normal hearing or mild hearing loss. The product transmits white noise non-invasively to the inner ear. White noise is sound in all frequencies, which means that people with both monotonous and polyphonic tinnitus tones can use Tinearity G1.